Matthew Root, DO
Interventional Pain Medicine · Sherman Oaks, CANPI 1043593098
Payments from drug & device makers
What this record shows
Vertiflex, Inc. accounts for 71.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $1,845 and has fallen 97.5% since, to $46 in 2022. That places this record below the midpoint for interventional pain medicine clinicians in CA, where the typical reported total is $3,134.
Across 28 payments — averaging $73.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertiflex, Inc.$1K
- Abbott$156
- Boston Scientific$87
- Nevro Corp.$82
- Biodelivery Sciences International, Inc.$67
- Flowonix Medical Incorporated$66
- plus $129 from 4 others
What the payments were for
- Travel & lodging$1,16156%
- Food & beverage$89644%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertiflex, Inc. | 9 | $1,469 |
| Abbott | 3 | $156 |
| Boston Scientific | 1 | $87 |
| Nevro Corp. | 2 | $82 |
| Biodelivery Sciences International, Inc. | 4 | $67 |
| Flowonix Medical Incorporated | 2 | $66 |
| Sentynl Therapeutics, Inc. | 4 | $61 |
| Stryker | 1 | $26 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Superion ISS$1,286
- Proclaim Family of SCS IPGs$123
How this compares
$2,056 in reported general payments places this provider in the 40th percentile of 188 interventional pain medicine providers in California.
See all interventional pain medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 51 | $62,528 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 434 | $16,661 |
| MovantikNaloxegol Oxalate | 22 | $10,040 |
| Oxycodone Hcl | 228 | $8,500 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 171 | $6,853 |
| Hydrocortisone Butyrate | 14 | $5,359 |
| Diclofenac Sodium | 35 | $4,721 |
| Gabapentin | 142 | $4,666 |
| Morphine Sulfate ErMorphine Sulfate | 105 | $2,633 |
| Morphine Sulfate | 76 | $2,626 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 25 | $2,100 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 73 | $1,869 |
| Pregabalin | 89 | $1,797 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 13 | $1,435 |
| Naloxone Hcl | 20 | $1,398 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Sherman Oaks
- Michael Verdolinla Mesa$507K
- Tim LeierRancho Mirage$449K
- Jonathan GrossmanVisalia$404K
- Kasra MaasumiRancho Santa Margarita$388K
- Andrew GermanovichRancho Mirage$333K
- David LeeYorba Linda$257K
- Standiford HelmOrange$254K
- Patrick BuchananCamarillo$219K
- Chau VuSanta Rosa$141K
- Phillip LimBuena Park$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.